MDT-AP-2638
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- C4
- umap1_2d
- 2.887503009
- umap2_2d
- 3.926667013
- umap1_3d
- 1.110889233
- umap2_3d
- -0.041843667
- umap3_3d
- -0.687833207
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.600
- INFLAMMATORY_RESPONSE+0.580
- TNFA_SIGNALING_VIA_NFKB+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- ALLOGRAFT_REJECTION+0.510
- INTERFERON_GAMMA_RESPONSE+0.510
- KRAS_SIGNALING_UP+0.510
- INTERFERON_ALPHA_RESPONSE+0.490
- COAGULATION+0.440
- COMPLEMENT+0.420
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- MYC_TARGETS_V1-0.610
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.530
- DNA_REPAIR-0.510
- WNT_BETA_CATENIN_SIGNALING-0.450
- MITOTIC_SPINDLE-0.420
- OXIDATIVE_PHOSPHORYLATION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.290
- NOTCH_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2892 | Med | Medulloblastoma | 0.959 |
| 2 | BS_W97QQYKQ | Ganglioglioma | — | 0.943 |
| 3 | ERR2598312 | fetal | fetal | 0.938 |
| 4 | BS_3H71BH6Q | Ganglioglioma | — | 0.935 |
| 5 | sclc0617_S65.txt | — | cohortMD2 | 0.935 |
| 6 | BS_1KYGSMA7 | low-grade glioma | — | 0.933 |
| 7 | MDT-AP-2743 | Med | Medulloblastoma | 0.931 |
| 8 | sclcWD22563_S71.txt | — | cohortMD2 | 0.931 |
| 9 | MDT-AP-2936 | Med | Medulloblastoma | 0.930 |
| 10 | BS_699TN5RN | Ganglioglioma | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.580 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.510 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |